Increased risk weighs on BIOSCRIP INCO., penalising its rating down to Slightly Negative
The independent financial analyst theScreener just lowered the general evaluation of BIOSCRIP INCO. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 14, 2019, the closing price was USD 2.22 and its target price was estimated at USD 1.47.BioScrip is a provider of infusion solutions. The company partners with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients access to post-acute care services. Whether in the home, physician office, ambulatory infusion center, nursing facility or other alternate sites of care, the company provides products, services and clinical management programs to improve the care of individuals with health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure. As of Dec 31 2017, the company had a total of 66 service locations in 27 states.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.